With $350 million in capital under management, A. M. Pappas & Associates has invested in over 65 portfolio companies in the United States and Canada. Their focus is on serving investors and entrepreneurs, while also supporting philanthropic interests in life sciences, public education, and entrepreneurial endeavors. The firm manages three lines of business, including Pappas Ventures, a family of life science venture capital funds with notable portfolio companies such as Ultragenyx Pharmaceutical and Chimerix. They also specialize in fund management and translational medicine initiatives, aiming to guide and manage academic-based translational product candidates to attract private investment or industry interest.